Celldex (NASDAQ:CLDX) announced today new data demonstrating profound, sustained complete response and improved quality of life at 76 weeks, 7 months after the completion of dosing with barzolvolimab ...

Patients with eosinophilic esophagitis in the US have high health care resource utilization costs, according to a retrospective national claims study.

Goldman Sachs 46th Annual Global Healthcare Conference Call June 10, 2025 9:20 PM ETCompany ParticipantsJames E.

In 2024, the cost and utilization of specialty dermatology drugs significantly drove a 7% increase in pharmaceutical costs, according to a June 10 report from Navitus Health Solutions, a pharmacy ...